首页 | 本学科首页   官方微博 | 高级检索  
     

兰特隆注射剂治疗晚期乳腺癌临床研究
引用本文:刘冬耕,管忠震,何友兼,沈镇宙,李宇红. 兰特隆注射剂治疗晚期乳腺癌临床研究[J]. 癌症, 1998, 0(6)
作者姓名:刘冬耕  管忠震  何友兼  沈镇宙  李宇红
作者单位:中山医科大学附属肿瘤医院内科,上海医科大学附属肿瘤医院
摘    要:目的:验证进口新药兰特隆对绝经后妇女晚期乳腺癌的临床抗肿瘤活性及不良反应。方法:前瞻性非对照临床研究,入组病人接受单药兰特隆肌肉注射,每次250mg,每两周一次。结果:共38例女性术后复发转移或不能手术的晚期乳腺癌病人进入临床试验。年龄41~80岁,中位年龄615岁。经过治疗9例(2368%)获得部分缓解,16例(4211%)病情稳定,13例(3421%)肿瘤进展。主要不良反应是注射部位疼痛(11例),未见骨髓及肝肾毒性。结论:兰特隆注射剂是一种对绝经后妇女晚期乳腺癌有一定疗效,不良反应轻的内分泌制剂。主要不良反应是注射部位疼痛,不影响治疗

关 键 词:乳腺肿瘤/药物疗法;兰特隆/治疗应用

A clinical trial of Lentaron injection in postmenopausalwomen with advanced breast cancer
Liu Donggeng Guan Zhongzhen He Youjian,et al.. A clinical trial of Lentaron injection in postmenopausalwomen with advanced breast cancer[J]. Chinese journal of cancer, 1998, 0(6)
Authors:Liu Donggeng Guan Zhongzhen He Youjian  et al.
Affiliation:Liu Donggeng Guan Zhongzhen He Youjian,et al.Medical oncology Department of Cancer Center,Sun Yat-SenUniversity of Medical sciences,Guangzhou 510060
Abstract:Objective:To test Lentaron's effect and side effect in postmenopausal women with advanced breast cancer.Methods:This is a prospective clinical trial without control.Patients received Lentaron injection 250mg alone every two weeks, 38 patients with relapse and/or metastatic breast cancer enrolled this study.Median age is 61 year.Results:After treatment,partial response was seen in 9 pts(23.08%),stable disease 16 pts (41.03%),progress disease 14 pts (35.89%).The main side effects are pain of injection and without bone marrow and liver/renal function damage.Conclusion:Lentaron alone is an effective endocrine drug with mild side effect in the treatment of postmenopausal women with advanced breast cancer.The main side effects are pain of injection and need not stop treatment.
Keywords:Breast Neoplasms/Drug therapy  Lentaron/therapeutics
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号